Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.
Transmasculine and gender-diverse individuals who use testosterone are not at increased risk of gynecological cancer in the first years of hormone therapy. This is evident from large-scale research by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results